Mycophenolate mofetil: a promising immunosuppressive agent.

Kulkarni, A A; Shah, Bharat V

Kulkarni, A A; Shah, Bharat V.

Article in English | IMSEAR | ID: sea-95099

ABSTRACT

ABSTRACT

With avaibility of newer immunosuppressive agents, incidence of acute graft rejection has decreased. Mycophenolate mofetil is one such new drug, now available in the Indian market It has been found to be useful in prevention and treatment of acute and chronic rejection after transplantation. Besides transplant it has been used successfully in primary and secondary glomerulopathies (e.g. SLE) and other autoimmune diseases. The drug is well tolerated with side effects limited mainly to gastrointestinal system in the form of epigastric pain, vomiting and diarrhoea.

Subject(s)

Aged; Area Under Curve; Biological Availability; Child; Clinical Trials as Topic; Drug Interactions; Graft Rejection/prevention & control; Half-Life; Humans; Immunosuppressive Agents/metabolism; Kidney Transplantation; Middle Aged; Mycophenolic Acid/analogs & derivatives; Tissue Distribution

Fulltext

XML

Search on Google

Full text: Available Index: IMSEAR (South-East Asia) Main subject: Aged / Humans / Biological Availability / Tissue Distribution / Child / Clinical Trials as Topic / Kidney Transplantation / Area Under Curve / Drug Interactions / Graft Rejection Type of study: Prognostic study Language: English Year: 2004 Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google